Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPGIOLI-PEREIRA, LucianaSANTOS, Paulo C. J. L.SUGAYA, Luisa S.FERREIRA, Noely E.KRIEGER, Jose EduardoPEREIRA, Alexandre C.HUEB, Whady A.2013-09-232013-09-232013BMC MEDICAL GENETICS, v.14, article ID 40, 7p, 20131471-2350https://observatorio.fm.usp.br/handle/OPI/1822Background: UCP2 (uncoupling protein 2) plays an important role in cardiovascular diseases and recent studies have suggested that the A55V polymorphism can cause UCP2 dysfunction. The main aim was to investigate the association of A55V polymorphism with cardiovascular events in a group of 611 patients enrolled in the Medical, Angioplasty or Surgery Study II (MASS II), a randomized trial comparing treatments for patients with coronary artery disease and preserved left ventricular function. Methods: The participants of the MASS II were genotyped for the A55V polymorphism using allele-specific PCR assay. Survival curves were calculated with the Kaplan-Meier method and evaluated with the log-rank statistic. The relationship between baseline variables and the composite end-point of cardiac death, acute myocardial infarction (AMI), refractory angina requiring revascularization and cerebrovascular accident were assessed using a Cox proportional hazards survival model. Results: There were no significant differences for baseline variables according genotypes. After 2 years of follow-up, dysglycemic patients harboring the W genotype had higher occurrence of AMI (p=0.026), Death+AMI (p=0.033), new revascularization intervention (p=0.009) and combined events (p=0.037) as compared with patients carrying other genotypes. This association was not evident in normoglycemic patients. Conclusions: These findings support the hypothesis that A55V polymorphism is associated with UCP2 functional alterations that increase the risk of cardiovascular events in patients with previous coronary artery disease and dysglycemia.engopenAccessUCP2A55V polymorphismCoronary artery diseaseDiabetesuncoupling protein-2 genecontrolled clinical-trial3 therapeutic strategiesenergy-expenditurediabetes-mellitusmass-iipromoteratherosclerosisangioplastymedicinearticleCopyright BIOMED CENTRAL LTD10.1186/1471-2350-14-40Genetics & Heredity